In an important minority of patients with chronic myeloid leukaemia (CML) on imatinib therapy, resistance has been observed, in most cases due to selection of cell clone variants that express BCR-ABL mutants with weakened imatinib-binding interactions. As part of efforts to combat resistance, secondgeneration tyrosine kinase inhibitors (TKIs) have been developed that are optimised for binding to mutated, imatinib-resistant BCR-ABL variants (dasatinib and nilotinib). 1,2 However, these drugs also apply selection pressure on BCR-ABL clones and can generate resistance, whereby the spectrum of resistance mutations is distinct from, but can overlap with, that of imatinib. 3, 4 Thus, upon shifting treatment to a new drug, secondary 'escape-mutant' clones of BCR-ABL-positive cells may emerge during treatment to become predominant in the total leukaemic population. In this scenario, heterogeneous cancer cell populations co-exist and undergo both selective and deselective processes upon drug exposure, but may not be eradicated completely even if a single clone achieves dominance. In this study, we evaluate the dynamics of variant BCR-ABL clones upon exposure to second-line drugs. The analysis of imatinib-resistant subjects at transition from first-to second-line TKI appeared particularly attractive for study, as the situation at the initiation of the salvage therapy comprises multiple BCR-ABL clones with diverse degrees of resistance that could be traced upon drug exposure.
The study was conducted as a retrospective, molecular analysis of 200 blood samples from 40 randomly selected CML patients that had been treated with 400-800 mg of imatinib and had acquired imatinib resistance as diagnosed by European LeukemiaNet (ELN) recommendations. 5 The patient data, derived from a comparative analysis of four genotyping approaches published recently, 6 comprise analyses of blood RNA samples taken before and 3, 6, 9 and 12 months after onset of second TKI. Complementary DNA synthesis was performed using random hexamer and MMLV reverse transcriptase. 7 BCR-ABL and beta-glucuronidase (GUS) transcripts were quantified as described previously. 8 Importantly, for the current study, mutations were considered to be significant only if detected by two independent methods (D-HPLC/DS, ARMS or L-PCR). Findings from only one method were excluded from further analysis. The significant mutations were analysed by quantitative real-time ARMS-PCR as described previously 9, 10 to determine the copy number of mutated transcripts. According to procedures established for assessment of leukaemic burden in CML (ratio BCR-ABL/GUS), mutated transcript burden was expressed as the ratio BCR-ABL mutated /GUS in percent. As all PCR reactions used in analysis were nearly 100% efficient, 9, 10 the calculated ratios were directly comparable, allowing a direct overlay of the resulting curves. Ratios derived from mutational analysis describe the absolute amount of transcription per cells harbouring a resistance mutation, rather than expressing resistance in relation to BCR-ABL-positive cells. The latter represents the most common way of analysing resistance in CML. Thus, following this novel approach we were able to describe absolute changes of the resistance burden conferred by a specific mutation (analysed by the BCR-ABL mutant /GUS ratio) in direct relation to changes in leukaemic burden (analysed by the BCR-ABL total /GUS ratio). A total of 59 mutated clones were detected in 28 patients harbouring one or more ABL KD mutations. In all, 13 patients had a single mutation, and the numbers of patients with two, three, four and five mutations were seven, four, two and two, respectively. Of the total 59 mutated clones, 48 included mutations that were part of our quantitative panel of assays and could be traced over time. Mutated clones not subjected to quantitative analysis held mutations L324Q, L387F, M388L, H396R/P, E459K and F486S. Thus, 81% of all mutated clones identified in the entire material were subjected to high-sensitive quantitative monitoring, providing a nearly complete systematic survey of quantitative changes upon transition from first-to second-generation CML drugs.
Based on the kinetics of BCR-ABL total /GUS (describing the leukaemic burden) versus BCR-ABL mutant /GUS (resistance burden conferred by the respective mutation) upon treatment change, several patterns of clonal evolution were observed. For the subjects with a single mutation, three basic patterns emerged: in eight subjects, a biphasic, parallel decrease of BCR-ABL mutant /GUS and BCR-ABL total /GUS (42 orders of magnitude), with no further emergence of mutations was observed; in two subjects, leukaemic burden reached a plateau after an initial parallel decrease of BCR-ABL mutant /GUS and BCR-ABL total /GUS, while the mutated isoform continues to decline; and in three subjects leukaemic and resistant subsets of BCR-ABL persisted throughout treatment (a case of T315I treated by dasatinib, and two cases of F359V and one of G250E, both treated by nilotinib).
In subjects harbouring multiple mutations, the variety of patterns was larger. In four subjects, the predominant mutation at treatment onset, in combination with a minor mutated clone, persisted or showed delayed response with the second TKI (E255V/K showed delayed response to dasatinib, Y253F/E255K and G250E persisted during nilotinib treatment). In the remaining 11 cases, the predominant mutation at treatment onset rapidly declined. However, although details of the patterns diverged, the decrease of a primary mutation was accompanied by stable, high BCR-ABL total /GUS ratios, whereby the primary mutation was supplanted by a secondary or in some cases sequentially by a tertiary clone.
As a first step, the study endpointsFquantitative data describing clonal evolutionFwere used to establish an in vivo mutational selectivity profile for dasatinib and nilotinib. For that purpose, BCR-ABL mutant /GUS values were transformed into log10 values and ratios of 3, 6, 9 and 12 months values to pre-treatment values were calculated for the two TKIs (Figure 1 ). For dasatinib (Figure 1a) , the largest increases in tumour subsets were observed for V299L and F317L, whereas T315I clones generally persisted during treatment. All other mutated clones were clearly sensitive to dasatinib, although the clones G250E or E255V had a smaller and delayed response. For nilotinib (Figure 1b) , E255V, G250E, F311I, E255K/V and F311I clones were rapidly selected (n ¼ 7); Y253H/F, T315I and F359V generally persisted (n ¼ 6), while F317L, M351T and E355G were sensitive (n ¼ 8). T315I again evolved slowly and the G250E was both selected and deselected upon treatment, indicating that there were additional determinants besides those characteristics of the mutant proteins themselves for these patients. In general, selection and deselection patterns observed were obvious as early as 3 months of treatment, in particular for patients receiving dasatinib. After initial rapid changes, most curves show saturation kinetics after 3 to 6 months, but in isolated cases clones decreased also at 12 months of drug exposure. Therefore, in an attempt to further characterise the in vivo drug sensitivity profile, clonal increase/decrease levels observed at 3 months of treatment were compared with quantitative measurements of in vitro resistance based on analysis of cell viability (IC50 analysis 3, 4 ). As shown in Table 1 , most of data agree with the in vitro results, which might be surprising, considering the heterogeneity of the approaches. However, for single mutations pronounced differences were found; in particular, for BCR-ABL T315I , the observed short-time kinetics are not in agreement with the high in vitro resistance shown by the IC50 levels of above 250. Thus, the comparisons highlight discrepancies between the in vivo and in vitro resistance settings, particularly for BCR-ABL T315I . Therefore, we sought to identify factors associated with selectivity patterns in vivo that are not operative in vitro. For that purpose, general patterns of dynamics observed in all individual subjects, harbouring multiple mutations, including those that harboured BCR-ABL T315I were evaluated (Figure 2 ). In apparent contrast to the distinct nature of T315I in IC50 measurements in vitro, the emergence of BCR-ABL T315I is not associated with immediate relapse kinetics; but rather, a slow and steady increase of the T315I subclones can be seen. Thus, despite the slow evolution of the T315I clones, it appears poised to become the dominant clone in several cases. Obviously, the BCR-ABL T315I observed in subject 15 is not in a position to replace the drug-sensitive BCR-ABL Y253H as rapidly as the BCR-ABL F317L does (subjects 7, 11 and 14). Although leukaemic burden is stabilized at a high level by the evolving BCR-ABL F317L (ratio never drops below 10%) in parallel to deselection of the BCR-ABL Y253H , the BCR-ABL T315I alone emerges slowly and therefore is associated with a drop in leukaemic burden to less than 1% (subject 15 and 22). Towards 12 months of 2nd TKI, BCR-ABL F317L levels drop, while BCR-ABL T315I is still increasing in subjects 7, 11. A more rapid replacement of existing clones is seen in cases 35 and 14: a dominating BCR-ABL T315I clone is rapidly replaced by a novel BCR-ABL E255K clone during nilotinib treatment, and a dominant BCR-ABL F317L is replaced by BCR-ABL V299L under dasatinib treatment. In these cases, competition between mutated clones apparently has a key role in the dynamic selectivity patterns. Consequently, as clonal interference obviously will not be instrumental in cell viability assays performed using mouse Ba/F3 cells in culture, clonal interference may be the origin of the many of the dynamic features observed in the study.
The key biological findings of this study are first, the observation of clonal competition in several subjects harbouring multiple mutations, and second, the variance of time scales of the apparent clonal competition. Understanding these phenomena is essential for improving treatment outcome in patients with polyclonal resistance. In our study, competition between individual subclones was observed at several levels. One of the most interesting phenomena observed for cases of multiple clones that include T315I is that other subtypes appear more rapidly, such as F317L or E255K, even though the T315I isoform always heads the list of resistant BCR-ABL isoforms in vitro.
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That a progression of successive dominant clones can be observed highlights the variance of the time scales (and operative mechanisms) required to achieve dominance.
These observations raise the question: How, and at which level(s), does the observed competition between drug-resistant clones occur? The rapid changes in selection and deselection of cell subsets after the change from first-to second-generation drugs highlight how drugs such as dasatinib or nilotinib affect the mechanisms active in clonal proliferation. The biphasic BCR-ABL transcript decline observed in patients that respond to imatinib provides data regarding drug distribution and effects on clones in various locales and/or stages of activity or differentiation. Measured activities and drug-binding properties of mutants such as T315I provide in vitro data relevant to drug modulation of the signalling functions of the BCR-ABL variants. A coherent picture that can explain the diversity of features described here will require a synthesis of such in vivo and in vitro data. Clonal competition may most readily be envisioned to take place at the stem-cell level. Considering possible scenarios, onset of new TKI therapy might alter interactions between BCR-ABL-positive stem cells and the bone marrow niche, thereby liberating resources for rapid use by a secondary (stem) cell resistant to second TKI. Interestingly, for the cases treated by dasatinib that harbour minor amounts of F317L and T315I before switching to the second TKI, the F317L subclone always appears first, whereas the T315I subclone appears later, together with a decline of F317. The observation of successive phases points towards several levels of competition between subclones, whereby rapid proliferation properties can confer early advantage, but slower properties enable longer-term survival. The elucidation of the various mechanisms is complicated by the fact that the measurements are conducted on peripheral blood, therefore those variations of population levels measured at the differentiated cell level in peripheral blood do not necessarily reflect the variations at the stem-cell level.
Competition between normal haematopoiesis, BCR-ABLpositive haematopoiesis and drug-resistant BCR-ABL clones has recently been described as substantial for CML, from Figure 1 In vivo selectivity of dasatinib and nilotinib towards mutated isoforms of BCR-ABL. BCR-ABL transcripts harbouring resistance mutations were traced over a 4-log range of magnitude. For each case, the absolute increase/decrease of single mutated clones from baseline (value at first significant detection) were calculated for dasatinib (a) or nilotinib treatment (b) and plotted as a function of time after first detection. The mutations can be ranked according to the increase, persistence or decrease patterns and classified into progressing, persisting and regressing clones for each drug. Letters to the Editor theoretical analysis and modelling of a series of CML responders. 11 According to that model of CML response, the biphasic BCR-ABL transcript decline observed after initiation of imatinib treatment arises from stem cells that populate two compartments, one quiescent and one proliferating. Transition from a quiescent to a proliferative state requires access to a limiting stem-cell niche, thus providing a setting for clonal competition. The proposed scenario has been discussed earnestly since publication, in particular with respect to models lacking competition phenomena. 12 Our data indirectly support Figure 2 Dynamic patterns of selection and deselection. The absolute levels of clones (copy-number-mutated transcripts or copy-number BCR-ABL transcript divided by copy-number housekeeping gene (%); BCR-ABL total /GUS ratio filled squares, straight lines; mutated clones stippled lines) is plotted as a function of secondary TKI treatment time in months. 'D' indicates treatment with dasatinib, 'N' nilotinib, the subsequent integer indicates the individual subject. (a) These patients showed patterns of polyclonal resistance, whereby a dominant clone and a minor clone both generally persist during treatment, although there is a 1-2-log variation in levels. (b) A common pattern involved one or more clones, initially minor, expanding to supplant the dominant clone during treatment. Especially, noteworthy is the slow growth or persistance of T315I mutant clones compared with many others. (c) Similar to the patterns of polyclonal resistance dynamics in b, T315I shows slow growth or persistence in these patients.
Letters to the Editor this theoretical model, as we clearly observe competition between co-existing drug-resistant clones. Moreover, because second TKI treatment in our study involves successive clonal selection and deselection processes at least partially at the stemcell level, TKI drugs such as dasatinib and nilotinib seem to target stem-cell subsets. Effective models must take this into account.
In conclusion, the imatinib follow-up drugs dasatinib and nilotinib inhibit the majority of imatinib-resistant BCR-ABL variants. However, the in-vivo resistance profiles described in this study show how cells harbouring critical mutations (V299L or F317L for dasatinib, Y253H/F, E255K/V and F359V for nilotinib, T315I for both) persist upon treatment or, alternatively, were rapidly selected. Upon quantitative follow-up of resistant clones, we identify a strong degree of clonal competition in subjects harbouring multiple mutations. This phenomenon might explain discrepancies of drug response observed between the in-vitro and in-vivo settings. Further studies implementing experimental settings particularly suited for studying competitional relations including modelling studies are needed in order for a comprehensive understanding of this phenomenon. Such studies need to include observation of for example, single-case studies that have implied competition also between native and mutated BCR-ABL. To elucidate mechanisms by which RUNX1-ETO, the common acute myeloid leukemia t(8;21) fusion protein, primes hematopoietic cells for oncogenic transformation, we previously carried out Affymetrix gene expression profiling of RUNX1-ETOexpressing human CD34 þ progenitor cells. 1 We identified the MYC target gene, MYCT1, as a gene significantly upregulated at an early developmental stage that could be integral to RUNX1-ETO-mediated leukemic phenotype (Figure 1 ). To determine whether increased MYCT1 expression recapitulates the RUNX1-ETO phenotype, we performed retroviral transduction of MYCT1 as a single molecular abnormality into hematopoietic cell lines and normal human cord blood-derived CD34 þ progenitor cells. In the absence of commercially available MYCT1 antibody, retroviral expression vectors, containing full-length MYCT1 coding sequence with (MYCT1-HA) or without (MYCT1) the addition of a C-terminal HA antigen tag, were also generated (Supplementary Materials and methods and Supplementary Figure S1 ), and transgenic MYCT1 overexpression was confirmed at the mRNA and protein levels (Supplementary Figure S2) . Functional validation (Supplementary Figure S3 ) was provided by replication of the reduced viability of MYCT1-expressing murine myeloid 32D cells in the absence of WEHI-3B-conditioned medium reported by Yin et al.
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Increased sensitivity to apoptotic stimuli has been reported for both RUNX1-ETO-expressing cells and cells in which MYC signalling is deregulated. 3 To determine the contribution of altered MYCT1 expression to primary myeloid progenitor cell viability, we performed cell survival assays using key hematopoietic cytokines. As shown in Figure 2a , cells transduced with MYCT1 showed significantly reduced intrinsic viability in the absence of serum and cytokine supplements: a five-fold reduction in number of viable MYCT1-expressing monocytes compared with GFP controls was measured after 48 h in culture. A lesser two-fold reduction in viable MYCT1-expressing granulocytes was also measured, suggesting that MYCT1 expression impacts on the survival of both lineages. Taken in combination with the reduced viability of MYCT1-expressing mouse 32D cells in the absence of IL-3, these results indicate that MYCT1 expression negatively impacts on survival or alters the threshold of trophic signalling required to prevent the activation of apoptosis in myeloid cells. MYCT1-expressing cells cultured in the presence of IL-3, SCF, G-CSF, IL-6, TNF-a or TPO experienced slightly reduced or unchanged viability compared with GFP control cells that only reached statistical significance at specific doses in cells of monocyte lineage (Supplementary Figure S3) . In striking contrast, MYCT1-expressing monocytes demonstrated a notable increase in cell survival responses to GM-CSF over a wide range of doses (Figure 2b) . The mean dose of GM-CSF required to support 50% maximal cell survival (defined as the number of live cells measured in the highest dose culture) was three-fold lower for MYCT1-expressing monocytes than GFP controls (data not shown). An increase in granulocytic cell survival was also observed but was not statistically significant (data not shown). These experiments unveil GM-CSF as unique amongst all cytokines assayed in its ability to counteract the substantially-diminished intrinsic viability of MYCT-expressing cells. MYCT1 may, therefore, be involved in the translation of anti-apoptotic signals from the GM-CSF receptor in myeloid cells and amplify the GM-CSF signalling that supports abnormal granulopoiesis in RUNX1-ETO-expressing cells, 4 promoting monocyte lineage in the absence of this oncoprotein. The different magnitude in responses between granulocytes and monocytes may reflect the differential activation of STAT3 and STAT5 downstream signalling components in these lineages. 5 To determine whether MYCT1 expression alters hematopoietic cell proliferative capacity as well as intrinsic viability, we performed bulk culture of MYCT1-expressing and GFP control populations, measuring live cell numbers over 30 days. Interestingly, no differences in viability of MYCT1-expressing cells were detected under these conditions of cytokine and serum sufficiency and, instead, a moderate but significant increase in population growth was observed over time (1.5-fold compared with GFP control after 21 days; Figure 3a ). This MYCT-driven expansion is in contrast to the absence of growth reported previously in MYCT1-expressing murine fibroblasts. 2 This disparity may reflect the context-dependent differential activity of MYCT1, highlighting an important role for this transcription factor in hematopoiesis. However, the former
